Survodutide (BI 456906) is a synthetic peptide functioning as a balanced dual agonist of the GLP-1 receptor and glucagon receptor (GcgR). It was designed to leverage complementary metabolic mechanisms: GLP-1R activation reduces caloric intake through central appetite signaling and promotes glucose-stimulated insulin secretion, while GcgR engagement is associated with increased energy expenditure, thermogenesis, and hepatic fat mobilization.
Dual Receptor Pharmacology Research
Research has examined survodutide's differential activity at GLP-1R and GcgR and the synergistic interactions between these two receptor pathways in preclinical and early clinical models.
Hepatic Metabolism and MASH Research
Preclinical and clinical research has examined survodutide in the context of metabolic dysfunction-associated steatohepatitis (MASH). The compound has been studied for its interactions with hepatic lipid accumulation, inflammation, and fibrosis signaling pathways.
Phase 3 Clinical Research
Survodutide progressed into Phase 3 clinical evaluation in the SYNCHRONIZE program. The SYNCHRONIZE-1 trial reported positive topline results in 2026, with participants experiencing average weight reductions of up to 16.6% over 76 weeks, meeting co-primary endpoints.
• Boehringer Ingelheim (2026). Survodutide met co-primary endpoints in SYNCHRONIZE-1 Phase III trial. Press release.
• Nahra R et al. (2021). Global Hepatic Biomarker Analysis with BI 456906 in Adults with Type 2 Diabetes. Diabetes Care, 44(4), 1042.